EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSLCRG00005020716
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSLCRG00005022928
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSLCRG00005013438
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSLCRG00005000532
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSLCRG00005006179
Gene Symbol: LOC104918784
3 Cross references
257 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSLCRG00005010799
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSLCRG00005022862
Gene Symbol: INSRA
3 Cross references
212 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSLCRG00005019382
Gene Symbol: INSRB
3 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSLCRG00005022856
Gene Symbol: IGF1RA
3 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSLCRG00005012567
Gene Symbol: IGF1RB
3 Cross references
203 Possible Orthologues:

Integrin Beta-1

Ensembl ID : ENSLCRG00005015017
Gene Symbol: LOC104934052
3 Cross references
228 Possible Orthologues:

Integrin Beta-3

Ensembl ID : ENSLCRG00005011246
Gene Symbol: LOC104926218
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).